Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Reata Pharmaceuticals stock | $136.74
Learn how to easily invest in Reata Pharmaceuticals stock.
Reata Pharmaceuticals, Inc is a biotechnology business based in the US. Reata Pharmaceuticals shares (RETA) are listed on the NASDAQ and all prices are listed in US Dollars. Reata Pharmaceuticals employs 261 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Reata Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RETA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Reata Pharmaceuticals stock price (NASDAQ: RETA)Use our graph to track the performance of RETA stocks over time.
Reata Pharmaceuticals shares at a glance
|Latest market close||$136.74|
|52-week range||$76.34 - $186.82|
|50-day moving average||$139.18|
|200-day moving average||$116.71|
|Wall St. target price||$237.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.06|
Buy Reata Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Reata Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Reata Pharmaceuticals price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-6.83%|
|3 months (2021-04-29)||35.39%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Reata Pharmaceuticals financials
|Revenue TTM||$8.6 million|
|Gross profit TTM||$-150,061,000|
|Return on assets TTM||-18.07%|
|Return on equity TTM||-89.06%|
|Market capitalisation||$4.7 billion|
TTM: trailing 12 months
Shorting Reata Pharmaceuticals shares
There are currently 3.8 million Reata Pharmaceuticals shares held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 9.6% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Reata Pharmaceuticals shares can be evaluated.
Reata Pharmaceuticals's "short interest ratio" (SIR)
Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals shares currently shorted divided by the average quantity of Reata Pharmaceuticals shares traded daily (recently around 486172.58883249). Reata Pharmaceuticals's SIR currently stands at 7.88. In other words for every 100,000 Reata Pharmaceuticals shares traded daily on the market, roughly 7880 shares are currently held short.
However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals shares, or, against the total number of tradable Reata Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Reata Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1277% of the tradable shares (for every 100,000 tradable Reata Pharmaceuticals shares, roughly 128 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Reata Pharmaceuticals.
Find out more about how you can short Reata Pharmaceuticals stock.
Reata Pharmaceuticals share dividends
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months.
Reata Pharmaceuticals share price volatility
Over the last 12 months, Reata Pharmaceuticals's shares have ranged in value from as little as $76.34 up to $186.817. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.5169. This would suggest that Reata Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals overview
Reata Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co. , Ltd.
Stocks similar to Reata Pharmaceuticals
Reata Pharmaceuticals in the news
RETA Makes Notable Cross Below Critical Moving Average
Is Reata Pharmaceuticals, Inc. (RETA) A Good Stock To Buy?
Tracking Baker Brothers Portfolio - Q1 2021 Update
Frequently asked questionsWhat percentage of Reata Pharmaceuticals is owned by insiders or institutions?
Currently 4.893% of Reata Pharmaceuticals shares are held by insiders and 81.241% by institutions. How many people work for Reata Pharmaceuticals?
Latest data suggests 261 work at Reata Pharmaceuticals. When does the fiscal year end for Reata Pharmaceuticals?
Reata Pharmaceuticals's fiscal year ends in December. Where is Reata Pharmaceuticals based?
Reata Pharmaceuticals's address is: 5320 Legacy Drive, Plano, TX, United States, 75024 What is Reata Pharmaceuticals's ISIN number?
Reata Pharmaceuticals's international securities identification number is: US75615P1030 What is Reata Pharmaceuticals's CUSIP number?
Reata Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75615P103
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert